Sientra Inc
NASDAQ:SIEN
Intrinsic Value
Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. [ Read More ]
The intrinsic value of one
SIEN
stock under the Base Case scenario is
6.04
USD.
Compared to the current market price of 0.09 USD,
Sientra Inc
is
Undervalued by 99%.
Sientra Inc's market capitalization is 1m USD.
SIEN stock price is 0.09 USD.
SIEN stock price (0.09 USD) is 99% less than its Intrinsic Value (6.04 USD).
SIEN.
SIEN's ROIC (Return on Invested Capital) has decreased in the last 3 years from -43% to -43%, and is approaching profitability.
SIEN's Revenue has grown by 2% over the past 12 months.
SIEN's Revenue has been growing by 14% per year for the last 3 years.
SIEN's long-term liabilties (172m USD) exceed its long-term assets (140m USD).
SIEN's ROE (Return on Equity) has significantly increased in the last 3 years from -553% to 326%.
SIEN has negative Operating Income for the last twelve months.
SIEN has negative Net Income for the last twelve months.
SIEN's ROE (Return on Equity) for the past 12 months is very high and is equal to 326%.
SIEN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -43%.
SIEN's short-term liabilties (152m USD) exceed its short-term assets (87m USD).
SIEN has positive Gross Profit for the last twelve months.
SIEN has very high three-year average ROE (Return on Equity): 38%. The company is very efficient at transforming stockholders' equity into net income.
SIEN has negative Free Cash Flow for the last twelve months.
SIEN has negative three-year average ROIC (Return on Invested Capital): -45%. The company is not efficient at using invested capital to generate operating income.
SIEN's D/E (Debt to Equity) is very low and is equal to 0.
SIEN's Altman Z-Score is very low and is equal to -8.57.
SIEN doesn't generate enough operating income (-56m USD) to safely cover interest payments on its debt (4m USD).
Fundamental Analysis
Sientra Inc
Balance Sheet Decomposition
Sientra Inc
| Current Assets | 86.5m |
| Cash & Short-Term Investments | 15m |
| Receivables | 29.6m |
| Other Current Assets | 41.9m |
| Non-Current Assets | 53.4m |
| PP&E | 19m |
| Intangibles | 33.5m |
| Other Non-Current Assets | 900k |
| Current Liabilities | 152.1m |
| Accounts Payable | 5.3m |
| Accrued Liabilities | 8.9m |
| Other Current Liabilities | 137.9m |
| Non-Current Liabilities | 19.9m |
| Other Non-Current Liabilities | 19.9m |
Earnings Waterfall
Sientra Inc
|
Revenue
|
90.3m
USD
|
|
Cost of Revenue
|
-52.3m
USD
|
|
Gross Profit
|
38m
USD
|
|
Operating Expenses
|
-93.6m
USD
|
|
Operating Income
|
-55.6m
USD
|
|
Other Expenses
|
-3.6m
USD
|
|
Net Income
|
-59.1m
USD
|
Free Cash Flow Analysis
Sientra Inc
What is Free Cash Flow?
SIEN Profitability Score
Profitability Due Diligence
Sientra Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
Score
Sientra Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
SIEN Solvency Score
Solvency Due Diligence
Sientra Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Score
Sientra Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SIEN Price Targets Summary
Sientra Inc
Ownership
SIEN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
SIEN Price
Sientra Inc
| Average Annual Return | -37.93% |
| Standard Deviation of Annual Returns | 45.65% |
| Max Drawdown | -100% |
| Market Capitalization | 1m USD |
| Shares Outstanding | 11 960 000 |
| Percentage of Shares Shorted | 11.1% |
Company Profile
Sientra Inc
Country
Industry
Market Cap
Dividend Yield
Description
Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. The company is headquartered in Santa Barbara, California and currently employs 319 full-time employees. The company went IPO on 2014-10-29. The firm's primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. The firm sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. Implant Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The firm also offers breast tissue expanders for reconstruction procedures predominantly to hospitals and surgery centers, and its BIOCORNEUM scar management products to plastic surgeons, dermatologists and other specialties. The firm's brands also include Platinum20, Sientra Smooth, Sientra Teardrop, Allox, Allox2, Anatomical Controlled, BIOCORNEUM, Curve, Luxe, Softspan, Silishield and AuraG.
You don't have any saved screeners yet
